FDA Approves Trikafta to Treat Children Starting at Age 6

FDA Approves Trikafta to Treat Children Starting at Age 6

296321

FDA Approves Trikafta to Treat Children Starting at Age 6

The U.S. Food and Drug Administration (FDA) has approved expanding the use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to children with cystic fibrosis (CF), ages 6 and older, who have at least one F508del mutation in the CFTR gene or a CFTR mutation that responds to Trikafta in laboratory studies. Use of the triple combination therapy, first approved in the U.S. in 2019, was previously limited to CF patients ages 12 and older with these mutations. According to Vertex…

You must be logged in to read/download the full post.